CliffBio
small molecule

DIFFERIN

ADAPALENE

Loss of exclusivityMay 2028latest FDA-listed patent expiry
CompanyGALDERMA LABORATORIES LP

Drug detail

Brand nameDIFFERIN
Active ingredientADAPALENE
Strength0.1%
Dosage formLOTION
RouteTOPICAL
ModalitySmall molecule
FDA approvalMarch 2010
Marketing statusDISCN

Listed patents

PatentExpiresType
7998467May 2028product
8435502September 2026product
8709392September 2026product

More from GALDERMA LABORATORIES LP

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DIFFERIN patent cliff — loss of exclusivity May 2028 | CliffBio